574.64MMarket Cap-2483P/E (TTM)
6.430High5.880Low1.21MVolume6.400Open6.540Pre Close7.28MTurnover1.78%Turnover RatioLossP/E (Static)95.61MShares13.50052wk High2.91P/B407.91MFloat Cap3.67052wk Low--Dividend TTM67.87MShs Float174.200Historical High--Div YieldTTM8.41%Amplitude1.904Historical Low6.036Avg Price1Lot Size
Cogent Biosciences Stock Forum
Positive 1b Data For Mastocytosis Therapy Announced By Major Biotech Company
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
Sorry a bit late! Grrrr! Was busy! Grrrr
GlobeNewswire· 30 mins ago
Ph2 readouts in Q1 2024...
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
Upcoming Ph 2 readouts in Q1 2024…
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
think Buffett want more of this company....
Big Repositioning on Witching Day
This was a sale that was planned ahead of time by the CEO of Moderna. It was not a random sale on the open market. But a few things to take away from this SEC filing. The transaction was planned to happen after the first half of the year during quad witching where repositioning volume is at its peak. This was a very large transaction and the CEO was only disposing shares of Moderna. There were a couple conversions of stock options but thery we...
No comment yet